Zi-En Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zi-En Qin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hai-Long Tan
Department of General Surgery Xiangya Hospital Central South University Changsha Hunan People's Republic of China
2 shared publications - Bo Wei
Department of General Surgery, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
1 shared publication Bo-Qiang Huang
Department of General Surgery, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
1 shared publication- Deng-Jie Ou-Yang
Department of General Surgery, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
1 shared publication - Gui-You Li
Department of General Surgery, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
1 shared publication - Huan Ge
Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital Central South University Changsha China
1 shared publication
Latest Publications
- Open Access
- 1 March 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (3) , 451-461
Prevalence of Hashimoto’s thyroiditis in papillary thyroid cancer and its association with aggressive characteristics
Background: Hashimoto’s thyroiditis (HT) has been associated with papillary thyroid cancer (PTC), yet whether the clinicopathological features of PTC are affected by HT remains unknown. The purpose of this study was to investigate the association of HT with clinicopathological features of PTC. Methods: We conducted a multicenter cross-sectional study to retrospectively evaluate the association of HT with clinicopathological features of PTC in the central provinces of China. The association between HT with clinicopathological features of PTC (including pathological HT and clinical HT) was evaluated by logistic regression analysis. Results: A total of 15,305 patients with PTC were enrolled to this study, with a median age of 42 years at diagnosis, including 11,465 women (74.9%) and 3,840 men (25.1%). The overall prevalence of HT in PTC patients was 22.9% (3,505/15,305). Compared with PTC patients without HT, pathological HT was a potential protective factor for several aggressive characteristics of PTC, including BRAFV600E mutation (PBRAFV600E mutation and bilateral tumors (PConclusions: PTC patients often have concomitant HT. Some potential links between the 2 entities are present. Pathological HT is a potential protective factor for some aggressive characteristics of PTC, whereas this effect does not present in clinical HT, which has guiding significance for clinical treatment decision-making.
- 1 March 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (3) , 451-461
Open AccessPrevalence of Hashimoto’s thyroiditis in papillary thyroid cancer and its association with aggressive characteristics
Background: Hashimoto’s thyroiditis (HT) has been associated with papillary thyroid cancer (PTC), yet whether the clinicopathological features of PTC are affected by HT remains unknown. The purpose of this study was to investigate the association of HT with clinicopathological features of PTC. Methods: We conducted a multicenter cross-sectional study to retrospectively evaluate the association of HT with clinicopathological features of PTC in the central provinces of China. The association between HT with clinicopathological features of PTC (including pathological HT and clinical HT) was evaluated by logistic regression analysis. Results: A total of 15,305 patients with PTC were enrolled to this study, with a median age of 42 years at diagnosis, including 11,465 women (74.9%) and 3,840 men (25.1%). The overall prevalence of HT in PTC patients was 22.9% (3,505/15,305). Compared with PTC patients without HT, pathological HT was a potential protective factor for several aggressive characteristics of PTC, including BRAFV600E mutation (PBRAFV600E mutation and bilateral tumors (PConclusions: PTC patients often have concomitant HT. Some potential links between the 2 entities are present. Pathological HT is a potential protective factor for some aggressive characteristics of PTC, whereas this effect does not present in clinical HT, which has guiding significance for clinical treatment decision-making.
- Open Access
- 30 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-10
A Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer
The health problems caused by the frequent relapse of papillary thyroid carcinoma (PTC) remain a worldwide concern since the morbidity rate of PTC ranks the highest among thyroid cancers. Residues from contralateral central lymph node metastases (con-CLNM) are the key reason for persistence or recurrence of unilateral papillary thyroid carcinoma (uni-PTC); however, the ability to assess the status of con-CLNM in uni-PTC patients is limited. To clarify the risk factors of con-CLNM, a total of 250 patients with uni-PTC who underwent total thyroidectomy and bilateral central lymph node dissection were recruited in this study. We compared the clinical, sonographic, and pathological characteristics of patients with con-CLNM to those without con-CLNM and established a nomogram for con-CLNM in uni-PTC. We found that male sex, without Hashimoto’s thyroiditis, present capsular invasion, with ipsilateral lateral lymph node metastases, and the ratio of ipsilateral central lymph node metastases ≥0.16 were independent con-CLNM predictors of uni-PTC (ORs: 2.797, 0.430, 2.538, 2.202, and 26.588; 95% CIs: 1.182–6.617, 0.211–0.876, 1.223–5.267, 1.064–4.557, and 7.596–93.069, respectively). Additionally, a preoperative nomogram for the prediction of con-CLNM based on these risk factors showed good discrimination (C-index 0.881; 95% CI: 0.840–0.923; sensitivity 85.3%; specificity 76.0%) and good agreement via the calibration plot. Our study provided a way to quantitatively and accurately predict whether con-CLNM occurred in patients with uni-PTC, which may guide surgeons to evaluate the nodal status and perform tailored therapeutic central lymph node dissection.
- 30 June 2021
- Published by Wiley in International Journal of Endocrinology
- Vol. 2021, 1-10
Open AccessA Prediction Model for Contralateral Central Neck Lymph Node Metastases in Unilateral Papillary Thyroid Cancer
The health problems caused by the frequent relapse of papillary thyroid carcinoma (PTC) remain a worldwide concern since the morbidity rate of PTC ranks the highest among thyroid cancers. Residues from contralateral central lymph node metastases (con-CLNM) are the key reason for persistence or recurrence of unilateral papillary thyroid carcinoma (uni-PTC); however, the ability to assess the status of con-CLNM in uni-PTC patients is limited. To clarify the risk factors of con-CLNM, a total of 250 patients with uni-PTC who underwent total thyroidectomy and bilateral central lymph node dissection were recruited in this study. We compared the clinical, sonographic, and pathological characteristics of patients with con-CLNM to those without con-CLNM and established a nomogram for con-CLNM in uni-PTC. We found that male sex, without Hashimoto’s thyroiditis, present capsular invasion, with ipsilateral lateral lymph node metastases, and the ratio of ipsilateral central lymph node metastases ≥0.16 were independent con-CLNM predictors of uni-PTC (ORs: 2.797, 0.430, 2.538, 2.202, and 26.588; 95% CIs: 1.182–6.617, 0.211–0.876, 1.223–5.267, 1.064–4.557, and 7.596–93.069, respectively). Additionally, a preoperative nomogram for the prediction of con-CLNM based on these risk factors showed good discrimination (C-index 0.881; 95% CI: 0.840–0.923; sensitivity 85.3%; specificity 76.0%) and good agreement via the calibration plot. Our study provided a way to quantitatively and accurately predict whether con-CLNM occurred in patients with uni-PTC, which may guide surgeons to evaluate the nodal status and perform tailored therapeutic central lymph node dissection.